Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies

What Was Tested

This randomized controlled trial paper looks at Romiplostim.

The thrombopoietin receptor agonist romiplostim is approved for second-line use in chronic immune thrombocytopenia (ITP), but its effects in patients with ITP for ≤1 year are not well characterized.

This analysis of pooled data from 9 studies included patients with ITP for ≤1 year (n = 311) or >1 year (n = 726) who failed first-line treatments and received romiplostim, placebo or standard of care.

Who Took Part

The abstract describes 9 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The patients were allocated by chance, so the Romiplostim group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Romiplostim could be set against what happens without it.

What Was Measured

The subject headings attached to it are Chronic Disease, Hemorrhage, Platelet Count, Purpura, Thrombocytopenic, Idiopathic, Receptors, Fc, Recombinant Fusion Proteins and Thrombopoietin.

Author keywords: immune thrombocytopenia, newly diagnosed, persistent and romiplostim.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Romiplostim in 9 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2019 (British journal of haematology), a journal based in England.

More context: the Romiplostim compound page, all human trials.